ArticleMicrobial cell factories2016
Metabolic engineering of Escherichia coli for the production of cinnamaldehyde.
Article in Microbial cell factories, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 83 citations in OpenAlex.
- Multi-gene Co-expression systems inSynthetic and systems biotechnology · 2026Review
- Engineering of Corynebacterium glutamicum for the enhanced production of optically pure (meso)-2,3-butanediol.Bioresources and bioprocessing · 2026Article
- Recent Advances on the Analysis and Biological Functions of Cinnamaldehyde and Its Derivatives.Antioxidants (Basel, Switzerland) · 2025Review
- Metabolic engineering of Escherichia coli for enhanced production of p-coumaric acid via L-phenylalanine biosynthesis pathway.Bioprocess and biosystems engineering · 2025Article
- A review of six bioactive compounds from preclinical studies as potential breast cancer inhibitors.Molecular biology reports · 2025Review
- Antiparasitic Activities of Acyl Hydrazones from Cinnamaldehydes and Structurally Related Fragrances.Antibiotics (Basel, Switzerland) · 2024Article
- Cinnamaldehyde in Focus: Antimicrobial Properties, Biosynthetic Pathway, and Industrial Applications.Antibiotics (Basel, Switzerland) · 2024Review
- Identification of a cinnamoyl-CoA reductase from Cinnamomum cassia involved in trans-cinnamaldehyde biosynthesis.Planta · 2024Article
- Integrated transcriptomics and metabolomics analysis provides insights into aromatic volatiles formation in Cinnamomum cassia bark at different harvesting times.BMC plant biology · 2024Article
- Efficient production of phenyllactic acid inFrontiers in microbiology · 2024Article
- Enzymatic reactions towards aldehydes: An overview.Flavour and fragrance journal · 2023Review
- Engineering microbes to overproduce natural products as agrochemicals.Synthetic and systems biotechnology · 2023Article
- Synergistic improvement of cinnamylamine production by metabolic regulation.Journal of biological engineering · 2023Article
- Review
- Construction and yield optimization of a cinnamylamine biosynthesis route in Escherichia coli.Biotechnology for biofuels and bioproducts · 2022Article
- Unleashing the potential of noncanonical amino acid biosynthesis to create cells with precision tyrosine sulfation.Nature communications · 2022Article
- Production of trans-cinnamic acid by whole-cell bioconversion from L-phenylalanine in engineered Corynebacterium glutamicum.Microbial cell factories · 2021Article
- Construction of recombinant Escherichia coli for production of L-phenylalanine-derived compounds.World journal of microbiology & biotechnology · 2021Review
- Transcriptomic Analysis of Resistant and Susceptible Responses in a New Model Root-Knot Nematode Infection System UsingFrontiers in plant science · 2021Article
- Efficient biosynthesis of cinnamyl alcohol by engineered Escherichia coli overexpressing carboxylic acid reductase in a biphasic system.Microbial cell factories · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPlant parasitic nematodes are harmful to agricultural crops and plants, and may cause severe yield losses. Cinnamaldehyde, a volatile, yellow liquid commonly used as a flavoring or food additive, is increasingly becoming a popular natural nematicide because of its high nematicidal activity and, there is a high demand for the development of a biological platform to produce cinnamaldehyde.
resultsWe engineered Escherichia coli as an eco-friendly biological platform for the production of cinnamaldehyde. In E. coli, cinnamaldehyde can be synthesized from intracellular L-phenylalanine, which requires the activities of three enzymes: phenylalanine-ammonia lyase (PAL), 4-coumarate:CoA ligase (4CL), and cinnamoyl-CoA reductase (CCR). For the efficient production of cinnamaldehyde in E. coli, we first examined the activities of enzymes from different sources and a gene expression system for the selected enzymes was constructed. Next, the metabolic pathway for L-phenylalanine biosynthesis was engineered to increase the intracellular pool of L-phenylalanine, which is a main precursor of cinnamaldehyde. Finally, we tried to produce cinnamaldehyde with the engineered E. coli. According to this result, cinnamaldehyde production as high as 75 mg/L could be achieved, which was about 35-fold higher compared with that in the parental E. coli W3110 harboring a plasmid for cinnamaldehyde biosynthesis. We also confirmed that cinnamaldehyde produced by our engineered E. coli had a nematicidal activity similar to the activity of commercial cinnamaldehyde by nematicidal assays against Bursaphelenchus xylophilus.
conclusionAs a potential natural pesticide, cinnamaldehyde was successfully produced in E. coli by construction of the biosynthesis pathway and, its production titer was also significantly increased by engineering the metabolic pathway of L-phenylalanine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.